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Background: The proteinase domain of the hepatitis C virus NS3 protein is
involved in the maturation of the viral polyprotein. A central hydrophobic domain
of the NS4A protein is required as a cofactor for its proteolytic activity. The
three-dimensional structure of the proteinase domain alone and complexed with
an NS4A-derived peptide has been solved recently and revealed that the
N terminus of the proteinase is in near proximity to the C terminus of the
cofactor. To study the molecular basis of the enzyme activation by its cofactor
and to overcome the difficulties of structural and functional investigation
associated with a two-species complex, we rationally designed a link to bridge
the two molecules in order to have a single polypeptide construct.
Results: The engineered construct led to the production of a stable,
monomeric protein with proteolytic activity that is independent from the addition
of a synthetic peptide representing the cofactor domain of the NS4A protein.
The protein is active on both protein and synthetic peptide substrates.
Spectroscopic and kinetic analysis of the recombinant NS4A–NS3 single-chain
proteinase demonstrated features superimposable with the isolated NS3
proteinase domain complexed with the NS4A cofactor.
Conclusions: We designed a very tight connection between the NS3 and
NS4A polypeptide chains with the rationale that this would allow a more stable
structure to be formed. The engineered single-chain enzyme was
indistinguishable from the NS3 proteinase complexed with its NS4A cofactor in
all enzymatic and physico-chemical properties investigated. 
Introduction
Hepatitis C virus (HCV) has been identified as the causal
agent of most transfusion-associated non-A non-B infec-
tions [1,2]. It afflicts millions of people worldwide and its
infection has a chronicity rate of about 70%. A high per-
centage of these patients have slowly progressive liver
disease ultimately leading to cirrhosis and hepatocarci-
noma [3,4]. During the past 10 years, tremendous progress
has been made in our understanding of the biology of
HCV but neither a vaccine nor an effective antiviral thera-
peutical agent has yet been developed.
HCV has a single-stranded RNA genome of about 9.6 kb
that encodes a precursor polyprotein of 3010–3030
residues [5]. The polyprotein is cleaved into individual
proteins upon proteolytic processing in specific regions of
the precursor. The N terminus of the precursor polypro-
tein comprises the structural proteins (C, E1, E2 and p7),
whereas the proteins encoded by the region NS2–NS5B
are identified as the nonstructural proteins. Viral matura-
tion and release are shown to be related to the activity of
host signal peptidases and viral-encoded proteinases
[6–19]. A zinc-dependent proteinase identified in the non-
structural region NS2/NS3 is responsible for the cleavage
at the NS2/NS3 cleavage site [10,11,20] whereas the pro-
teolytic cleavage at the NS3/NS4A, NS4A/NS4B,
NS4B/NS5A and NS5A/NS5B sites is mediated by a chy-
motrypsin-like viral serine proteinase encoded within the
NS3 protein [7,9,11,13]. NS3 is a 70 kDa protein compris-
ing a proteinase domain, located in the first 180 N-termi-
nal residues [16,21–25], and a helicase domain, at its
C terminus [26]. Although the NS3 serine proteinase is
capable of basal proteolytic activity, it requires the 54-
residue NS4A protein as an activator [16,21,27,28]. The
two proteins are present in solution as a heterodimer and
numerous biochemical observations suggest this to be the
catalytically active proteinase [23,29–33]. Deletion and
mutagenesis studies have shown that the central
hydrophobic region comprising residues 21–34 of NS4A is
sufficient to interact with the N-terminal portion of the
NS3 proteinase domain thus enhancing its proteolytic
activity; furthermore, recent studies have shown that the
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NS3 cleavage efficiency can be activated by synthetic
peptides encompassing residues 21–34 of the NS4A
protein [30,34–37].
The three-dimensional structures of the NS3 proteinase
domain alone and complexed with the synthetic peptide
representing the activating region of NS4A have been
determined recently [38–40], confirming several conclu-
sions derived from molecular modelling predictions and
biochemical studies [41–43]. The enzyme reveals an
overall folding typical of the chymotrypsin-like serine pro-
teinases and a structural zinc-binding site [42,44]. The
structures of the NS3 proteinase alone and complexed
with its cofactor differ substantially in the N-terminal part
of the molecule. In the non-complexed structure, the first
30 residues of the enzyme form four β strands involved in
crystal packing with neighbouring molecules. In the
NS3–NS4A complex structure, the NS4A cofactor
assumes a β-strand secondary structure and interacts with
the N-terminal region of the enzyme. The latter region in
the complex forms a planar β–α–β structure with the
α helix perpendicular to the two β strands. The β strand
formed by NS4A intercalates between the two β strands
contributed by the N terminus in an antiparallel fashion.
The helix connecting the two N-terminal β strands of
NS3, α0, is juxtaposed against the N terminus of the
NS4A peptide. The structural rearrangements upon cofac-
tor binding ultimately affect the entire N-terminal β barrel
of the NS3 proteinase and result in the realignment of the
proteinase catalytic triad in a ‘canonical’ arrangement.
Analysis of the crystal structure of the complexed pro-
teinase suggests a very tight binding between NS3 and its
NS4A co-factor, due to the large number of interactions
that give rise to an extended surface area (about 2,400 Å2)
buried upon complex formation. In agreement with its
large buried surface area, the NS3–NS4A complex has
been shown to be very stable in the cytoplasm of cultured
cells expressing the HCV polyprotein [29]. This observa-
tion is in striking contrast to the relatively high equilib-
rium dissociation constant of the complex between
purified NS3 and the NS4A peptide cofactor measured in
solution [45]. The instability of the complex between the
NS3 proteinase domain and the NS4A peptide cofactor in
solution has been related to the structural features of
helix α0: in this helix, all the residues facing outwards and
away from the rest of the protein are bulky hydrophobic
amino acids. Exposing such a large hydrophobic surface to
an aqueous solvent would be, from a thermodynamic point
of view, extremely costly in terms of free energy; there-
fore, the formation of helix α0 may be largely unfavoured
in aqueous solution, whereas it might promptly form in
the membranous environment in which the NS3–NS4A
complex is normally located [28]. It has in fact been
argued that the crystal structure of the NS3–NS4A
complex may represent the membrane-bound form of the
proteinase [40] rather than the structure adopted by the
complex in solution.
The limited stability of the complex between the NS3
proteinase and the NS4A peptide has some undesirable
practical consequences. It implies, for example, the use of
a large molar excess of the NS4A peptide cofactor in order
to drive complex formation when the NS3 proteinase is
used to carry out enzymatic assays or for spectroscopic
investigations [45,46]. In order to overcome the inherent
instability of the NS3–NS4A complex and on the basis of
the crystallographic structure, we set out to design a fusion
protein in which the cofactor is covalently bound to the
N terminus of the NS3 enzyme by a rigid short loop. If the
connecting loop were properly designed, we expected the
intramolecular interaction between the NS4A fragment
and the NS3 proteinase to be greatly favoured over the
intermolecular interaction observed in the case of the
bimolecular complex. In addition, the success of our
design would provide evidence that a conformation similar
to that observed in the crystal structure could be adopted
by the NS3 proteinase in solution.
In this paper, we describe the overexpression and the char-
acterisation of a single-chain NS3–NS4A proteinase
whereby the activator is fused at the N terminus of the pro-
teinase domain. Expression of this construct in Escherchia
coli cells resulted in the production of a highly soluble, con-
stitutively activated proteinase–activator complex that
could represent an extremely useful tool with which to
screen and identify effective HCV inhibitors. This single-
chain proteinase could also represent an extremely valuable
candidate for structural studies of proteinase–substrate
analogs or proteinase–inhibitor complexes.
Results
Design of the NS4A–NS3 single-chain proteinase
The structure of the HCV proteinase complexed with a
peptide corresponding to residues 21–34 of the NS4A
cofactor shows that the cofactor is essentially buried
within the core of the enzyme and forms an antiparallel β
sheet with two of the enzyme’s strands (Figure 1a). There
are extensive interactions between the cofactor and
several regions of the enzyme. The C-terminal residue of
the cofactor peptide and the N terminus of the NS3
protein are very close to each other in the crystal structure.
The distance between Ser32–C and Thr4–O is 4.3 Å. This
suggests that it should be possible to connect the two
polypeptides by a short loop. Our aim was to design a very
tight turn, with the rationale that this might overcome the
intrinsic instability of the complex between the NS3 pro-
teinase and the NS4A peptide cofactor.
We chose to design a type I hairpin loop [47] connecting
residue Ser32 of the NS4A-derived peptide and Thr4 of the
NS3 proteinase domain for two reasons. Firstly, a search in
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the Brookhaven database for hairpins showing the correct
distance between their termini preferentially selected type
I hairpins. Secondly, this class of loops has a preference for
proline in position L1 (i.e. in the first of the two residues
forming the loop) and we considered the rigidity of proline
a desirable property to achieve a more stable structure. We
selected the sequence Pro-Ser (the most commonly
observed for type I loops) and modelled it with backbone
dihedral angles corresponding to a right-handed α-helical
conformation, with a virtual torsion angle (the dihedral
angle defined by the Cα of the residue before the loop, of
the two residues in the loop and of the subsequent residue)
of about 50°. A database search confirmed that such a con-
formation is in fact quite frequent and in more than 20% of
these cases the first residue of the loop is a proline.
Figure 1a shows the model of the designed chimeric
protein. The resulting molecular architecture of the
single-chain NS4A–NS3 proteinase is shown schemati-
cally in Figure 1b. NS4A residues 21–32 were followed
by the engineered turn with the sequence Pro-Ser. The
turn sequence is followed by amino acids 4–180 of the
NS3 protein. The N-terminal sequence Met-Ala-Lys was
engineered to promote high expression levels of the
recombinant protein, according to the N-end rule [48].
Finally, the C terminus of the proteinase was modified to
include the sequence Ala-Ser-Lys-Lys-Lys-Lys in order
to increase the solubility of the single-chain proteinase.
Construction and characterisation of the NS4A–NS3 single-
chain proteinase
In order to test the functionality of the single-chain
protein for trans-cleavage activity, the recombinant
protein was expressed by cell-free transcription/translation
(Figure 2). Both single-chain and wild-type NS3 pro-
teinases were translated in vitro from appropriate RNA
and labelled with [35S]methionine. 35S-labelled
NS5A–NS5B∆C51 HCV precursor protein was used as
substrate. Proteolytic activity experiments were per-
formed incubating equal volumes of the translated
enzymes with the translated substrate for 30 min at room
temperature, in the presence or absence of a large excess
of an NS4A-derived synthetic peptide (Pep4AK). Figure 2
shows that the NS5A cleavage product was yielded in the
samples containing the single chain, both in the presence
and absence of Pep4AK (Figure 2, lanes 6,7). Conversely,
no product was detectable with the NS3 enzyme in the
absence of Pep4AK (Figure 2, lane 4).
NS4A–NS3 single-chain protein was overexpressed in a
soluble form in E. coli (Figure 3a). Comparison of the
soluble and insoluble fractions of the extract of E. coli cells
before and after induction revealed that the recombinant
enzyme was expressed as soluble protein without the for-
mation of inclusion bodies. About 90% of the induced
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Figure 1
(a) Cα trace of the NS3 protease complexed with region 21–34 of the
NS4A cofactor. The NS4A-derived peptide is shown in green. The
catalytic triad residues are in ball-and-stick representation. The
backbone of the designed loop (including Ser32 of NS4A) is shown in
red and superimposed onto the X-ray structure. (b) Schematic
representation of the recombinant NS4A–NS3 single-chain proteinase.
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Figure 2
Protease activity of the in vitro translated NS3 protease domain and
NS4A–NS3 single-chain protease on in vitro translated protein
substrate NS5A–NS5B∆C51. Lane 1: control sample of the in vitro
translated NS4A–NS3 single-chain protease. Lane 2: control sample
of the in vitro translated NS3 protease domain. Lane 3: control sample
of the in vitro translated substrate NS5A–NS5B∆C51. Lane 4: NS3
protease + NS5A–NS5B∆C51. Lane 5: NS3 protease + NS5A–
NS5B∆C51 + 16 µM Pep4AK. Lane 6: NS4A–NS3 single chain
(SC) + NS5A–NS5B∆C51. Lane 7: NS4A–NS3 SC + NS5A–
NS5B∆C51 + 16 µM Pep4AK. The protein bands corresponding to
the substrate (NS5A–NS5B∆C51) and to the product (NS5A) are
indicated by arrows. The complementary product, NS5B∆C51, was
not detected in the gel system used because of its small size.
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protein was recovered directly in the soluble fraction of
the crude extract as detected by Coomassie-stained SDS
gel (Figure 3a; lane 4). The NS4A–NS3 proteinase crude
extract was purified by batch filtration on
DEAE–Sepharose (Pharmacia) followed by an
SP–Sepharose column and gel filtration on a Superdex 75
column. A final ion-exchange chromatography on a
Resource S column was used to remove residual contami-
nants and to concentrate the protein. The protein was
purified to near-homogeneity (> 95%) as judged by
SDS–PAGE (Figure 3b; lanes 1,2) and HPLC analysis
(data not shown). The purified NS4A–NS3 proteinase
cross-reacted with rat monoclonal antibodies raised against
the NS3 proteinase domain (Figure 3b; lanes 3,4). N-ter-
minal sequence analysis showed the removal of the N-ter-
minal methionine and that the resulting N-terminal
sequence was Ala-Lys-Gly-Ser-Val-Val-Ile-Val. Liquid
chromatography mass spectrometry gave a molecular
weight value of 20,936 ± 0.8, in good accordance with the
expected single-chain protein molecular weight after
removal of the N-terminal methionine, thereby indicating
a uniform C terminus. The purification protocol yielded
about 8 mg of pure protein per litre of culture, which
could be concentrated up to 10 mg/ml.
We next addressed the issue of the functionality of the
engineered enzyme by assessing its ability to recognise
and cleave synthetic substrates. Activity experiments were
performed using an 18-mer peptide derived from the
NS5A–NS5B cleavage site [36]. The peptide substrate
was incubated for 10 min at room temperature with the
single-chain proteinase either in the absence or in the
presence of Pep4AK. Figure 4 shows the comparison of
both the single-chain and the NS3 proteinase activity in
the absence and presence of the peptide cofactor under
the same experimental conditions. The cleavage effi-
ciency of the single-chain enzyme was not affected at all
by the presence of Pep4AK, which is known to increase
the cleavage efficiency of the isolated NS3 proteinase
domain on similar substrates [45,46]. The kinetic analysis
of the NS5A–NS5B peptide substrate cleavage reaction
was performed under the same buffer conditions. Table 1
reports the kinetic parameters for the single-chain pro-
teinase compared with the NS3 proteinase activated by
Pep4AK. Again, comparable values were obtained for both
enzymes within the experimental error.
The data shown so far demonstrate that the enzymatic
activity of the engineered single-chain NS4A–NS3 pro-
teinase is experimentally indistinguishable from that of
the isolated NS3 proteinase domain complexed with an
NS4A-derived synthetic peptide. This could possibly be
achieved by establishing an intramolecular interaction
between the proteinase domain and the N-terminal-fused
NS4A sequence, as predicted by our design. Alternatively,
multimerization of the single-chain enzyme could activate
the NS3 serine proteinase by the intermolecular interac-
tion of the NS4A sequence of one molecule with the NS3
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Figure 3
Electrophoretic analysis of the overexpression
and purification of NS4A–NS3 single-chain
(SC) protease. (a) Coomassie-stained
SDS–PAGE. Lane 1: non-induced cells.
Lane 2: induced cells. Lane 3: crude extract
after cell disruption. Lane 4: clarified
supernatant. Lane 5: DEAE filtrate. Lane 6:
insoluble fraction of the crude extract.
(b) Coomassie-stained (lanes 1,2) and
immuno-stained (lanes 3,4) SDS–PAGE:
Lanes 1,3: Superdex 75 fraction. Lanes 2,4:
purified NS4A–NS3 single-chain protease.
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Figure 4
Comparison of the protease activity of the NS3 protease domain and
the NS4A–NS3 single-chain protease. 5 µM NS5A–NS5B 18-mer
peptide substrate was incubated for 10 min at room temperature with
the NS3 protease domain or with the NS4A–NS3 single-chain
protease (2 nM), both in the absence and presence of 16 µM Pep4AK
in an activity buffer containing 50 mM Hepes pH 7.5, 15% glycerol,
0.1% Triton X-100, 10 mM DTT and 0.15 M NaCl.
100
80
60
40
20
%
 M
ax
im
al
 a
ct
iv
ity
–Pep4A
+Pep4A
–Pep4A +Pep4A
NS3 protease Single chain
Folding & Design
proteinase domain of a second molecule. In this second
case, the fold adopted by the single-chain enzyme would
differ significantly from our model.
In order to determine whether the activation of the single-
chain NS3 proteinase could be mediated by the multimer-
ization of the enzyme under the activity assay conditions,
we measured its enzymatic activity as a function of the
protein concentration in the range 0.15–5 nM. Figure 5a
shows that the specific activity of the enzyme is constant
throughout the enzyme concentration range used. This
finding suggests that the recombinant single-chain pro-
teinase is either active as a monomeric species, or forms
active multimers that are stable in the subnanomolar
range. To resolve the issue, we investigated the associa-
tion state of the protein in the micromolar range by size
exclusion chromatography. The protein analysed with this
method showed a single protein peak eluting with a
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Table 1
Comparison of the kinetic parameters of the NS4A–NS3
single-chain protease and the NS3 protease domain
complexed with Pep4AK.
Km (µM) Kcat (min–1)
NS4A–NS3 SC 11.0 37
NS4A–NS3 SC + Pep4AK 10.5 36
NS3 protease > 400 < 2
NS3 protease + Pep4AK 9.6 41
The activity assays were performed in 50 mM Hepes pH 7.5, 0.1%
Triton X-100, 15% glycerol, 150 mM NaCl and 10 mM DTT. The
concentrations of the enzymes and Pep4AK were 2 nM and 16 µM,
respectively. The substrate (Glu-Ala-Gly-Asp-Asp-Ile-Val-Pro-Cys-Ser-
Met-Ser-Tyr-Thr-Trp-Thr-Gly-Ala) was added to start the reaction in the
concentration range 0.3–60 µM. The values reported are the average
of at least four independent determinations.
Figure 5
Oligomerization state of the NS4A–NS3
single-chain protease in solution.
(a) Dependence of NS4A–NS3 single-chain
protease velocity and specific activity on
protein concentration. The purified
NS4A–NS3 single-chain protease was
incubated with 20 µM NS5A–NS5B substrate
at different concentrations of the enzyme in
the range 0.15–5 nM. (b) Analytical gel
filtration. Elution profile of NS4A–NS3 single-
chain proteinase from the analytical Superdex
75 column. The arrows indicate the molecular
mass standards.
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volume corresponding to the molecular weight of the
expected NS4A–NS3 proteinase in a monomeric form
(Figure 5b). Size exclusion chromatography was performed
in the presence of different detergents and at different
ionic strengths to ascertain whether the experimental con-
ditions could affect the association/aggregation state of the
protein. The purified protein was loaded at different
protein concentrations onto an analytical Superdex 75
column previously equilibrated with a buffer containing
0.15 or 0.5 M NaCl in the presence of 0.1% CHAPS or
0.1% n-octyl-β-D-glucopyranoside. In both cases, the
enzyme eluted as a single protein peak with the molecular
mass corresponding to the monomeric form. This suggests
that the engineered enzyme is active as a monomer and
does not undergo association upon variation of ionic
strength condition (in 150 mM NaCl and in 0.5 M NaCl).
Parallel studies (N.D., unpublished data) on an alternative
NS3 proteinase linked at the N terminus with its NS4A
cofactor by virtue of a di-Gly loop reported that the protein
elutes from gel filtration as a monomeric protein at low
ionic strength, whereas the same protein reversibly associ-
ated into a trimer by increasing the NaCl concentration.
Fluorimetric and CD analysis of NS4A–NS3 single-chain
enzyme
The structural changes induced by the formation of a
complex between the truncated NS3 proteinase and a
peptide spanning NS4A residues 21–34 can be monitored
by changes in the protein near-UV circular dichroism (CD)
spectrum and in its tryptophan fluorescence spectrum [45].
These spectroscopic changes were interpreted in terms of
changes in the environment of Trp85, which is engaged in
the interaction with the sidechain of Val23 of NS4A. In
order to demonstrate that the engineered single-chain
NS4A–NS3 proteinase is folded as expected, its fluores-
cence emission properties and its near-UV CD spectra
were compared with those of the NS3 proteinase domain
in the presence and absence of Pep4AK cofactor. Intrinsic
protein fluorescence allows conformational differences to
be detected with high sensitivity, as both the amplitude
and the wavelength of maximum emission are strongly
affected by the fluorophores and their local environment.
As illustrated in Figure 6a, the fluorescence spectrum of
the single-chain proteinase coincides with that of the
NS3–Pep4AK complex within the limits of experimental
error. The addition of excess Pep4AK to the single-chain
enzyme did not promote any significant changes in the
protein fluorescence spectrum (data not shown). On the
other hand, the addition of Pep4AK to the NS3 proteinase
domain resulted in an increase of the tryptophan fluores-
cence as was reported in analogous studies on HCV BK
strain NS3 proteinase domain [45]. The same conclusion
can be drawn from the analysis of the near-UV CD spectra,
which clearly reveals that the environment of the aromatic
chromophores is similar in the case of the NS3–Pep4AK
complex and in the single-chain NS4A–NS3 construct
(Figure 6b). We therefore conclude that the designed
single-chain polypeptide and its noncovalent counterpart
(NS3 + Pep4AK) are indistinguishable from each other
with respect to their spectroscopic properties.
Discussion
The three-dimensional crystal structure of the NS3 pro-
teinase has revealed that significant conformational
changes occur upon NS4A cofactor binding. These
changes are most obvious in the rearrangement of the N-
terminal region. In the structure of the isolated NS3 pro-
teinase domain, the N-terminal 30 amino acids of NS3
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Figure 6
Comparison of the spectral properties of the NS4A–NS3 single-chain
protease and NS3 protease domain in the presence and absence of
Pep4AK. (a) Fluorescence spectra of NS3 protease, NS3 protease
+ Pep4AK and NS4A–NS3 single-chain (SC) protease. The excitation
wavelength is set at 280 nm. (b) Near-UV CD spectra of NS3 protease,
NS3 protease + Pep4AK and NS4A–NS3 single-chain protease.
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extend away from the protein core and interact with
hydrophobic surface patches of neighbouring molecules in
the crystallographic asymmetric unit. Conversely, in the
crystal structure of the complex, the same region forms
two elements of secondary structure, strand A0 and helix
α0, that fold as a molecular clamp locking the NS4A cofac-
tor onto the NS3 proteinase domain (Figure 1a). Strik-
ingly, in contrast with the large surface of interaction, the
complex between the NS3 proteinase domain and the
NS4A peptide cofactor has been found to be only margin-
ally stable in solution, raising the possibility that the con-
formation observed in the complex crystal structure may
not represent the one adopted by the enzyme in solution.
In this respect, it is interesting to note that in one of the
published complex crystal structures, only one of the
monomers in the crystallographic asymmetric unit is
folded in the way just described. In the second monomer,
the first 30 residues do not have a defined structure
despite the presence of the NS4A cofactor bound in
exactly the same position [38]. All these observations
suggest that binding to the NS4A peptide cofactor might
be necessary but not sufficient to promote the folding of
the NS3 N-terminal arm as seen in the complex crystal
structure, and that multiple conformations of this region
may exist in solution even in the presence of the cofactor.
The experiments described in the present study show that
by inserting a short rigid loop between the C terminus of
the NS4A peptide and the N terminus of NS3, we were
able to generate a constitutively active proteinase
complex. The single-chain enzyme we designed is indis-
tinguishable from the HCV NS3 proteinase domain com-
plexed with an NS4A peptide cofactor in terms of all the
enzymatic and spectroscopic properties investigated. The
devised purification protocol was straightforward and
yielded several milligrams of 95% pure protein. The
protein could be expressed in a soluble and monomeric
form and was proven to be highly active without the need
of exogenously added NS4A cofactor. The effect of
NS4A-derived peptides on tryptophan fluorescence and
on enzymatic activity have been used previously to deter-
mine the stability of the complex [45]. The spectroscopic
data on the single-chain proteinase suggest that the aro-
matic residues of NS3, namely Trp53 and Trp85, do not
experience any relevant changes of their physicochemical
environment with respect to the noncovalent complex.
Although we and others have previously reported the con-
struction of functional single-chain NS3–NS4A fusion pro-
teins ([49–51]; N.D., unpublished data) whereby the
NS4A cofactor was tethered to the NS3 protein by means
of a covalent peptide linker, this paper represents the first
example of a structure-based design of a single-chain
enzyme that can be expressed in E. coli at high level as a
soluble functional enzyme without the requirement for
laborious refolding procedures. Our results are consistent
with a stable intramolecular interaction between the NS3
proteinase domain and its covalently linked NS4A activa-
tor. Furthermore, the success of our structure-based
design suggests that the single-chain NS4A–NS3 pro-
teinase adopts a fold very similar to that observed in the
crystal structure of the NS3–NS4A complex. Thus, the
covalent linkage between the NS3 N terminus and the
NS4A cofactor domain via a structurally constrained type I
hairpin turn appears to help overcome the instability of
the N-terminal region observed when the NS3 protein is
complexed with an NS4A-derived synthetic peptide.
Structural studies by X-ray and NMR on the single-chain
proteinase are currently under way in our laboratory in
order to confirm in detail the success of our design.
The mechanism of trans activation of the NS3 proteinase
by its NS4A cofactor is still an open issue and may have
important implications for the development of an anti-
HCV therapy. The NS4A–NS3 single-chain protein could
represent an extremely useful tool to overcome the diffi-
culties of biochemical analysis of ternary complexes in the
screening of potential enzyme inhibitors. The single-chain
protein could also represent an interesting alternative for
structural investigations of complexes between the
enzyme and its substrates/inhibitors.
Materials and methods
Design and modelling
Insight [52] was used for structural analysis and database loop
searches. We also used the database search tools of WHATIF [53].
Recombinant DNA techniques
Standard DNA protocols were used to insert the cDNA fragments in
the expression vectors of interest [54]. pT7-J-NS3K4 plasmid encoding
the J strain HCV proteinase domain [55] was used as a template for
the PCR reactions. The HCV J strain NS4A–NS3 single-chain pro-
teinase was obtained by a two-step PCR and cloned downstream of a
T7 promoter gene 10 in a pT7-7 plasmid [56]. The synthetic oligonu-
cleotide used at the 5′-end (5′-GCATTACAACATATGGCTAAAGGTT-
CCGTTGTTATCGTTGGTCGTATCATCCTGTCCCCGTCCACGGCC
TATTCCCAACAAACGCGGGGCCTG-3′) contains the NdeI restric-
tion site, the triplets encoding the amino-acid sequence Met-Ala-Lys,
NS4A residues 21–32, a polypeptide linker with the sequence Pro-Ser
and the sequence encoding residues 4–13 of J strain NS3 proteinase
coding sequences. At the 3′-end, the oligonucleotide comprises the
sequence complementary to nucleotides of the J stain HCV NS3 pro-
teinase, a solubilising sequence (Ala-Ser-Lys-Lys-Lys-Lys), a stop
codon and an EcoRI restriction site (5′-TTTGAATTCCTACTTCTTCTT-
CTTGCTAGCCCGCATGGTAGT-3′). The resulting PCR fragment
was digested with NdeI and EcoRI and cloned into the pT7-7 plasmid
digested with the same enzymes. The whole gene was subsequently
sequenced in order to rule out the presence of undesired mutations.
In vitro transcription and translation
A pCiteNS5A/NS5B construct encoding the NS5A/NS5B polyprotein
cleavage site was linearised with an appropriate restriction enzyme
(NS5A/NS5B∆C51) and its translated protein used as substrate
according to reference. Recombinant plasmids pT7-J-NS3K4 and
pT7NS4A-NS3, representing the truncated NS3 proteinase domain
(residues 1–180) and the single-chain polypeptide respectively, were
linearized and transcribed in vitro with T7-RNA polymerase (Strata-
gene). The transcripts were translated in the presence of [35S]methion-
ine for labelling using an RNA-dependent rabbit reticulocyte lysate
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(Promega) according to the supplier’s recommendation. The translated
proteins were added to adequate amounts of in vitro translated sub-
strate NS5A/NS5B∆C51. The activity reactions were carried out at
room temperature in either the absence or presence of 16 µM
Pep4AK. The reactions were stopped after 30 min upon addition of
20 µl of SDS sample buffer, heated at 95°C for 5 min, then resolved
onto 12% SDS–PAGE and analysed by autoradiography.
Expression and purification
The recombinant plasmid carrying the coding sequence for the
NS4A–NS3 single chain was transformed into BL21(DE3) E. coli cells.
Single colonies were grown overnight in a modified M9 minimal
medium [57] containing 100 mM potassium phosphate pH 7.0, 5 g/l
glucose, 1 g/l ammonium sulphate, 5 mM biotin, 7 mM thiamine, 0.5%
casamino acids, 0.5 mM MgSO4, 0.5 mM CaCl2, 13 mM FeSO4⋅×7H2O,
100 mM ZnCl2, 50 mg/l ampicillin. A 1/10 dilution of an overnight
culture was used to innoculate 2 litres of the same medium and grown
to an OD600 of 0.6–0.8 at 37°C. Expression of the protein was
obtained by the addition of 0.4 mM IPTG and 0.1 mM of ZnCl2, cells
were grown for further 4–6 h at 22°C, harvested by centrifugation and
stored at –20°C. All the purification steps were performed at 4°C on an
FPLC System (Pharmacia). The cells were resuspended in 1/20 of the
original volume in lysis buffer containing 25 mM sodium phosphate
pH 6.5, 10% glycerol, 200 mM NaCl, 1% CHAPS, 6 mM DTT and a
cocktail of proteinase inhibitors (COMPLETE, Boehringer) and dis-
rupted with 20 strokes in a Microfluidizer (Microfluidics Corp. Massa-
chusetts) at a pressure of 60 psi. The extract was clarified by
centrifugation at 40,000 × g for 30 min.
The clarified crude extract was mixed with a DEAE–Sepharose Fast
Flow resin (Pharmacia) equilibrated in 25 mM sodium phosphate
pH 6.5, 10% glycerol, 200 mM NaCl, 0.1% CHAPS, 3 mM DTT (buffer
A), and filtered in a Buchner funnel. The filtrate was loaded onto an
SP–Sepharose column (Pharmacia) previously equilibrated with buffer
A, exhaustively washed with the same buffer and eluted with a 0.2–1 M
NaCl linear gradient. The desired fractions, between 0.5 and 0.6 M
NaCl, were pooled, concentrated on a YM10 membrane in a stirred
ultrafiltration cell (Amicon) and loaded onto a preparative gel filtration
column (HR 60/600 Superdex 75, Pharmacia) equilibrated with buffer
B (50 mM sodium phosphate pH 7.5, 10% glycerol, 200 mM NaCl,
0.1% CHAPS, 3 mM DTT). The protein peak was collected and loaded
onto a Resource S column (Pharmacia) and eluted in a pure form by
applying a 0.1–0.4 M NaCl linear gradient in buffer A. Protein concen-
tration, throughout the purification protocol, was determined with the
Bio-Rad protein assay using BSA as standard. A coefficient of 19,300
was used for the pure NS4A–NS3 single chain. The enzyme purity was
analysed by 12% SDS–PAGE detected either by Coomassie blue
staining or by Western blot using anti-NS3-specific rat monoclonal
antibodies. The anti-NS3 rat monoclonal immunoglubulin G (IgG)
Y0NS3P4/46.D8 was raised against a purified NS3 proteinase frag-
ment encompassing amino acids 1027–1206 of the HCV J strain
polyprotein. The enzyme purity was also monitored by HPLC using a
reverse phase Vydac C4 column. Purified protein was further charac-
terised by LC mass spectrometry performed on a Perkin-Elmer API 100
instrument and by N-terminal analysis carried out using Edman degra-
dation on an Applied Biosystem model 470A gas-phase sequencer.
Peptides and HPLC assays
Pep4AK synthesis was performed as described in Steinkuhler et al.
[46]. The synthetic peptide substrate (Glu-Ala-Gly-Asp-Asp-Ile-Val-Pro-
Cys-Ser-Met-Ser-Tyr-Thr-Trp-Thr-Gly-Ala) derived from the
NS5A–NS5B cleavage site (J strain) was purchased from Bachem.
When not differently specified, cleavage assays were performed at
room temperature in a buffer containing 50 mM Hepes, pH 7.5, 0.1%
Triton X-100, 15% glycerol, 150 mM NaCl and 10 mM DTT. As pro-
teinase cofactor, we used the synthetic Pep4AK peptide. 16 µM
Pep4AK was pre-incubated for 10 min with the appropriate amount of
protein and reactions were started by addition of substrate. Incubation
times were chosen in order to obtain < 10% substrate conversion.
Reactions were stopped by addition of 40 µl of 1% TFA. Cleavage of
peptide substrates was determined by HPLC using a Merck-Hitachi
chromatograph equipped with an autosampler. Samples of 80 µl were
injected on a Lichrospher C18 reversed phase cartridge column
(4 × 75 mm, Merck) and fragments were separated using a 10–90%
acetonitrile gradient using a flow rate of 2.5 ml/min. Peak detection
was accomplished by monitoring both the absorbance at 220 nm and
the tryptophan fluorescence of the product (excitation wavelength
280 nm, emission wavelength 350 nm). The amounts of cleavage prod-
ucts were calculated by integration of chromatograms with respect to
appropriate standards.
Gel filtration chromatography
A Superdex 75 HR 10/30 prepacked column (Pharmacia) was used to
estimate the apparent molecular weight of the recombinant single-
chain protein under native conditions. The protein was loaded onto a
column equilibrated with 50 mM sodium phosphate pH 7.5, 10% glyc-
erol, 0.1% n-octyl-β-D-glucopyranoside, 3 mM DTT containing either
0.15 or 0.5 M NaCl at a constant flow rate of 0.4 ml/min on an FPLC
System. Molecular mass marker proteins used to calibrate the column
were: blue dextrane (2,000 kDa), BSA (66 kDa), ovalbumin (44 kDa),
NS3 proteinase domain (19 kDa) and ribonuclease (13 kDa).
Circular dichroism and fluorescence spectroscopy
Fluorescence measurements were performed on an LS50B Perkin
Elmer spectrofluorimeter using 1 cm pathlength quartz cuvettes. Fluo-
rescence emission spectra were recorded at 300–400 nm at 20°C,
with the excitation wavelength set at 280 nm with the same spectral
bandwidth of 5 nm for both excitation and emission. Cofactor binding
experiments were performed by incubation of 16 µM Pep4AK with
either the single-chain proteinase or the proteinase domain in 2.5 ml of
50 mM Hepes, pH 7.5, 0.1% CHAPS, 15% glycerol, 150 mM NaCl
and 3 mM DTT at a protein concentration of 0.5 µM. Spectra were
recorded before and after addition of Pep4AK. CD measurements
were performed with a Jasco J-710 spectropolarimeter equipped with a
cell holder thermostatically controlled at 15°C. The protein concentra-
tion used was 50 µM for the NS3 proteinase domain and 40 µM for the
NS4A–NS3 single-chain proteinase. 65 µM Pep4AK was used for the
cofactor binding experiments. Near-UV measurements were carried out
at 250–310 nm in a 1 cm pathlength quartz cuvette. The results are
expressed as the differential molar circular dichroic extinction coeffi-
cient (∆ε).
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